The latest biotech news

Nabriva story bacterial pneumonia antibiotic

News and Trends 20 Aug 2019

Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic

The US FDA has approved Nabriva Therapeutics’ Xenleta for treating community-acquired bacterial pneumonia, the first in a new class of antibiotics developed to treat this condition. Xenleta, also known as lefamulin, was discovered almost 10 years ago by Nabriva Therapeutics, a spinout company from Novartis split between Austria, Ireland and the US. The approval is […]

August 20, 2019 - 3 minutesmins - By Helen Albert

News and Trends 16 Aug 2019

First Potential Chlamydia Vaccine Shows Early Promise

A vaccine targeting the sexually transmitted infection chlamydia, which would be the first of its kind if approved, has proved safe and able to stimulate the immune system in a phase I trial. In the phase I trial, the vaccine was injected into 35 healthy women. Blood samples from the volunteers were then measured to […]

August 16, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 15 Aug 2019

Swiss Scientists Upgrade CRISPR to Edit Many Genes at Once

A research group at ETH Zurich, Switzerland, has made it possible to edit hundreds of genes at once with CRISPR gene editing. CRISPR gene editing has revolutionized the biotech industry by providing an easy and quick way to genetically modify organisms. So far, however, CRISPR techniques have only managed to edit a maximum of seven […]

August 15, 2019 - 3 minutesmins - By Jonathan Smith

mallinckrodt regenerative medicine skin graft bioprinting skin

News and Trends 14 Aug 2019

Engineered Skin Shows Potential to Treat Burns in Phase I

Engineered skin tissue, developed as a regenerative medicine by the UK-US pharma company Mallinckrodt, has reduced the need for skin grafts in burns victims in a phase Ib trial. The phase I trial tested Mallinckrodt’s engineered skin treatment in 29 patients suffering from deep second degree burns. Patients with these burns have damage to the […]

August 14, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 13 Aug 2019

AskBio Acquires Scottish Biotech to Make Gene Therapies More Precise

The US company AskBio has acquired the Edinburgh-based Synpromics to pool their gene therapy technologies and produce inducible gene therapies that target particular organs or cells. AskBio specializes in developing viral vectors that carry gene therapies into cells, such as adeno-associated virus, whereas Synpromics develops DNA sequences called promoters that drive the expression of gene […]

August 13, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 12 Aug 2019

Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months

The UK biotech Autolus’ shares have slumped as construction delays from a new manufacturing site have pushed back its CAR-T cell immunotherapy programs. Autolus is developing treatments for blood cancer that involve engineering patients’ own immune cells to kill cancer cells, known as autologous CAR-T cell immunotherapies. Earlier this year, Autolus licensed a new manufacturing […]

August 12, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 7 Aug 2019

Late-Stage Clinical Trial Troubles for Dry Eye Disease Drug

A drug developed by the UK company Topivert Pharma has failed to reduce eyeball grittiness sensations in patients with dry eye disease in a phase II/III trial. The trial tested Topivert’s small molecule drug given as eyedrops to 202 patients suffering from dry eye disease, a condition where not enough tears are produced to lubricate […]

August 7, 2019 - 2 minutesmins - By Jonathan Smith

adc therapeutics genomics sophia genetics blood cancer

News and Trends 6 Aug 2019

ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment

Two companies based in Lausanne, Switzerland — ADC Therapeutics and the genomics company SOPHiA Genetics — have signed a deal to identify patients most likely to respond to a blood cancer drug. ADC Therapeutics will send SOPHiA Genetics blood samples collected from an ongoing phase II trial. The trial is testing a treatment for patients […]

August 6, 2019 - 2 minutesmins - By Jonathan Smith

oncolytic virus cancer treatment transgene sillajen

News and Trends 2 Aug 2019

Oncolytic Virus for Liver Cancer Ruled Futile in Phase III

A phase III trial testing an oncolytic virus treatment for liver cancer, developed by the French biotech Transgene, has been discontinued after interim analyses concluded that the treatment was unlikely to succeed. Originally expected to finish in 2020, the phase III trial tested the oncolytic virus treatment Pexa-Vec in patients with the liver cancer hepatocellular […]

August 2, 2019 - 2 minutesmins - By Jonathan Smith

inflammatory bowel disease treatment personalized medicine predictimmune

News and Trends 31 Jul 2019

British Biotech Raises €11M to Market Personalized Medicine Test

The UK biotech PredictImmune has raised €11M (£10M) in a Series B fundraising round to commercialize technology to predict the progress of inflammatory bowel disease in newly diagnosed patients. The funds will finance the global launch of PredictSURE IBD, a blood test that can identify patients with the most severe cases of inflammatory bowel disease, […]

July 31, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 31 Jul 2019

Wellington Partners Raises €210M to Invest in European Life Sciences

VC firm Wellington Partners has raised its fifth fund dedicated to investing in life science companies, with a major focus on those located in German-speaking countries. Wellington Partners has well surpassed its initial target of €150M for its fifth life sciences fund. With a total €210M raised, this new fund is more than double the […]

July 31, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Jul 2019

French Biotech’s Insulin Resistance Treatment Boosted by €67M Series A

The French company Alizé Pharma III has raised a Series A round of €67M to push two peptide drugs into phase I, including a drug treating rare genetic conditions causing insulin resistance. The money will advance Alizé Pharma III’s two preclinical drugs into clinical trials, with phase I trials expected to begin in 2020. One […]

July 31, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic

First Potential Chlamydia Vaccine Shows Early Promise

Swiss Scientists Upgrade CRISPR to Edit Many Genes at Once

Engineered Skin Shows Potential to Treat Burns in Phase I

AskBio Acquires Scottish Biotech to Make Gene Therapies More Precise

Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months

Late-Stage Clinical Trial Troubles for Dry Eye Disease Drug

ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment

Oncolytic Virus for Liver Cancer Ruled Futile in Phase III

British Biotech Raises €11M to Market Personalized Medicine Test

Wellington Partners Raises €210M to Invest in European Life Sciences

French Biotech’s Insulin Resistance Treatment Boosted by €67M Series A

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!